Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Divalent cation-dependent enzyme refers to a broad class of catalytic proteins that require the presence of two-plus charged metal ions, such as magnesium (Mg2+), zinc (Zn2+), or manganese (Mn2+), for their biological activity (Holm et al., 1996, Chemical Reviews). These ions typically reside within the enzyme active site, where they facilitate catalysis by stabilizing negative charges on transition states, activating nucleophiles like water, or properly orienting substrates (Andreini et al., 2008, Journal of Proteome Research). This category includes several high-profile therapeutic targets, such as HIV-1 integrase, matrix metalloproteinases (MMPs), and histone deacetylases (HDACs) (Pommier et al., 2005, Nature Reviews Drug Discovery; Overall and Kleifeld, 2006, Nature Reviews Cancer). Drugs targeting these enzymes often employ metal-binding groups, such as hydroxamates or carboxylates, to coordinate directly with the divalent cation and displace essential water molecules or substrates (Cohen, 2007, Current Opinion in Chemical Biology). Because these metal ions are ubiquitous and essential for the function of many different enzymes, a major challenge in drug design is achieving sufficient selectivity to avoid off-target toxicity (West and Johnstone, 2014, Journal of Clinical Investigation). Consequently, while these enzymes are vital targets for treating viral infections, cancer, and hypertension, their structural similarities require precise pharmacophore modeling to ensure safety and efficacy. The diversity of this class means that divalent cation-dependent enzyme is a functional grouping rather than a single protein family, encompassing a wide range of structural folds and biological pathways.
Inhibition through coordination with active-site divalent cations, preventing substrate binding or transition state stabilization (Cohen, 2007, Current Opinion in Chemical Biology).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Divalent cation-dependent enzyme.